title: Intracoronary administration of different doses of anisodamine in primary percutaneous coronary intervention: protective effect in patients with ST-segment elevation myocardial infarction.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effects of intracoronary administration of anisodamine on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) undergoing a primary percutaneous coronary intervention (pPCI).
  
  
  METHODS
  Patients with acute STEMI undergoing pPCI were enrolled in this randomized-controlled study (January 2014-June 2015) and divided randomly into four groups: group A (normal saline), group B (1000 μg anisodamine), group C (2000 μg anisodamine), and group D (4000 μg anisodamine).
  
  
  RESULTS
  The study group included 140 patients. Percentages of thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade 3, increased values of TIMI myocardial perfusion grade after stenting, and decreased values of corrected TIMI frame count in groups B, C, and D were all significantly higher than those in group A (P=0.031, 0.027, 0.003, and P<0.001, respectively). TIMI frame count after stenting in groups B, C, and D was significantly lower than that in group A (P=0.001). Left ventricular ejection fraction at 1 week after pPCI and at the 3-month follow-up, as well as the major adverse cardiac event-free survival rate in groups B, C, and D were higher than those in group A (P=0.027, 0.016, and 0.019, respectively).
  
  
  CONCLUSIONS
  Intracoronary administration of anisodamine at different doses improved myocardial reperfusion in patients with STEMI undergoing pPCI and reduced major adverse cardiac events. The protective effect of anisodamine at a dose of 4000 μg might be better than the doses at 1000 and 2000 μg.
authors.affiliation: Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
authors.forename: Shiru
authors.initials: S
authors.lastname: Bai
authors.forename: Xianghua
authors.initials: X
authors.lastname: Fu
authors.forename: Xinshun
authors.initials: X
authors.lastname: Gu
authors.forename: Yanbo
authors.initials: Y
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Yanming
authors.initials: Y
authors.lastname: Fan
authors.forename: Liye
authors.initials: L
authors.lastname: Wei
authors.forename: Xile
authors.initials: X
authors.lastname: Bi
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002681:China; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D055414:Myocardial Perfusion Imaging; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation; D000072657:ST Elevation Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D012991:Solanaceous Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects; D015607:Stents; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D012991:Solanaceous Alkaloids; C003922:anisodamine